Association of age, AMH, and gonadotropin dosing on IVF outcomes in fertility preservation cycles for patients less than 35 undergoing chemotherapeutic treatment: A retrospective cohort study

年龄、抗苗勒氏管激素(AMH)水平和促性腺激素剂量与接受化疗的35岁以下患者生育力保存周期中体外受精(IVF)结局的关系:一项回顾性队列研究

阅读:1

Abstract

OBJECTIVE: To evaluate the differences in total number of oocytes and MII oocytes retrieved with gonadotropin dosing in adolescent and young adult patients compared to older patients undergoing fertility preservation cycles for cancer diagnosis. DESIGN: Retrospective cohort. SETTING: Single academic institution. PATIENT(S): All patients less than 35 years old undergoing a fertility preservation cycle who have a cancer diagnosis, or a plan to receive gonadotoxic chemotherapy. INTERVENTION(S): Fertility preservation cycles in patients < 22 years old (younger group) compared with those 22- < 35 years old (older group) stratifying by age, AMH, and average daily gonadotropin dosing. MAIN OUTCOME MEASURE(S): Total oocyte yield, total number of MII oocytes. RESULTS: The younger group had 26% more oocytes retrieved and 28% more MII oocytes retrieved compared with the older group, when adjusting for BMI, chemotherapy prior to treatment and myelodysplasia (aRR 1.28, 95% CI 1.01-1.63). Starting, total, and average daily gonadotropin doses were similar between age groups. Cycles in the younger group (10.0%) were more likely to be canceled compared with the older group (2.8%) (RR 3.52, 95% CI 1.35-0.17); 35.9% of the younger group and 11.7% of the older group had chemotherapy prior to cycle start. CONCLUSION(S): Patients should be encouraged to undergo fertility preservation prior to receiving chemotherapy as this commonly decreases ovarian reserve and leads to a higher likelihood of cycle cancellation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。